G-CSF Dimer Neuroprotection Parkinson Alzheimer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases, such as Parkinson's and Alzheimer's, are inadequate in effectively preventing neuronal loss and have significant side effects, with existing medications requiring frequent administration and offering limited therapeutic benefits.
Innovation Solution
A G-CSF dimer with a prolonged serum half-life is developed, which acts as a pharmaceutical composition to increase dopamine levels in the corpus striatum, prevent dopaminergic neuron loss, and enhance neuronal function, thereby improving symptoms and treatment efficacy for neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If G-CSF monomer is used for treatment of neurodegenerative diseases, then therapeutic effect is achieved, but frequent administration is required due to short half-life
Solution Approach 1:
The patent combines two G-CSF monomers to form a dimer structure, where the two monomeric units are linked together through their Fc regions. This merging of two identical functional units results in a single molecule with extended serum half-life, allowing less frequent administration while maintaining therapeutic efficacy.
2Quantity of substance
If levodopa is used for Parkinson's disease treatment, then dopamine levels are replenished, but neuronal loss cannot be prevented and side effects occur
Solution Approach 1:
The patent converts the harmful effect of neuronal loss into a beneficial outcome by using G-CSF dimer to protect and preserve dopaminergic neurons. Instead of merely replacing dopamine (which doesn't prevent neuronal death), the G-CSF dimer activates protective signaling pathways that prevent neuronal apoptosis, thereby converting the problem of neuronal loss into a therapeutic mechanism that preserves the neuron population.
3Reliability
If G-CSF is administered at high dosage for neurodegenerative diseases, then therapeutic response is achieved, but treatment duration is extended and patient compliance decreases
Solution Approach 1:
The patent changes the pharmacokinetic parameter of serum half-life by creating a dimer structure. This parameter change allows the drug to maintain effective concentrations for longer periods, reducing the total treatment duration needed to achieve therapeutic response and improving patient compliance without compromising efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The G-CSF dimer significantly increases dopamine levels, inhibits dopaminergic neuron loss, and improves neuronal function, providing a more effective and convenient treatment option for neurodegenerative diseases with reduced frequency of administration.
Implementation Method 1
G-CSF Receptor (G-CSFR) is proven to exist mainly in bone marrow hematopoietic stem cells Sca+Lin-Thllow, precursor cells CD34+, committed granulocyte precursor cells, and mature neutrophils. G-CSFR is a specific receptor having a high affinity to G-CSF
Implementation Method 2
The G-CSF dimer significantly increases dopamine levels, inhibits dopaminergic neuron loss, and improves neuronal function
Data Source
Figure 1~4
Figure 5A~5B
Figure 6A~6B
AI summary
The invention discloses the use of the G-CSF dimer in the preparation of a medicament for the treatment of neurodegenerative diseases. Use of the G-CSF dimer of the present invention can significantly increase the number of dopaminergic neuron in the substantia nigra in PD model animals and enhance the function of dopaminergic neurons. In addition, the G-CSF dimer can significantly reduce apoptosis of neuron in hippocampus and improve learning and memory ability of AD model rats. Serum half-life of the G-CSF dimer of the invention is prolonged and the loss of neurons is effectively prevented, providing a better therapeutic effect in treatment of neurodegenerative disease.